Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CPG10101 Combination Therapy For The Treatment Of Hepatitis C: A Phase 1b Open Label Randomized Trial Of CPG10101 Alone, With Interferon, Ribavirin, Or Interferon And Ribavirin In The Treatment Of Relapsed Hepatitis C Virus (HCV) Subjects

NCT00142103 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00142103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00142103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CPG10101 Combination Therapy For The Treatment Of Hepatitis C: A Phase 1b Open Label Randomized Trial Of CPG10101 Alone, With Interferon, Ribavirin, Or Interferon And Ribavirin In The Treatment Of Relapsed Hepatitis C Virus (HCV) Subjects
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2005
Completion date
February 28, 2007
Enrollment
91 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis, chronic active